Regulatory Affairs and Quality Assurance Specialist, Faculty of Pharmacy, Ahfad University for Women, Sudan
*Corresponding author
Online published on 29 January, 2026.
Understanding eligibility for drug patents and exclusivities is essential for protecting innovations in the competitive pharmaceutical sector. When a pharmaceutical company develops a new drug, a patent protects this invention from unauthorized use, ensuring that the inventor can recoup the research and development costs throughout the product's lifecycle.
This article discusses the various types of protections for pharmaceutical products granted by intellectual property offices and regulatory authorities, highlighting the differences and similarities between the United States and Europe. By demonstrating patent protection and regulatory exclusivity, the article provides insight into the specific regulations and criteria that must be met to obtain a patent and the associated exclusivity rights.
In the United States, there are Patent Term Adjustment (PTA) and Patent Term Extension (PTE), and in Europe, there is the Supplementary Protection Certificate (SPC). This article illustrates these protection rights and compares their main features. Additionally, it presents straightforward scenarios that outline the key elements that influence the determination and calculation of the protection period, as well as the timely launch of products into the market.
Drug Development, Patent, Exclusivity, United States Patent and Trademark Office (USPTO), United States Food and Drug Administration (USFDA), European Medicines Agency (EMA), European Patent Office (EPO), European Supplementary Protection Certificate (SPC), Patent Term Adjustment (PTA), Patent Term Extension (PTE)
